Featured Articles

Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive…
Read More...

Pfizer Inc. announced the closing of its joint venture with GlaxoSmithKline plc to combine the parties’ respective consumer healthcare businesses to create the world’s largest…
Read More...

Novartis announced Kisqali (ribociclib) achieved statistically significant improvement in overall survival in the Phase III MONALEESA-3 clinical trial. This is the second Phase III…
Read More...

Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection). Myxredlin (pronounced…
Read More...

Sandoz, a Novartis division and a global leader in biosimilars, announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar…
Read More...

Celltrion and Nan Fung Group announced the establishment of Vcell Healthcare Limited, a Joint Venture company between both parties. At the formation of the Joint Venture, Vcell…
Read More...

MilliporeSigma and the Broad Institute of MIT and Harvard announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada)  announced that Lynparza (olaparib) has been approved in Japan as a…
Read More...

Gilead Sciences, Inc. and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic…
Read More...

Pfizer Inc. and Array BioPharma Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical…
Read More...

Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy in…
Read More...

Bayer and Arvinas, a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins, announced an agreement to leverage Arvinas’ novel PROTAC protein…
Read More...

Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an…
Read More...

Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, announce that they have signed a manufacturing…
Read More...

Allergan plc and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental New Drug…
Read More...

Merck, known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Merck, through…
Read More...

Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development…
Read More...